Boston Partners’s Novo Nordisk NVO Stock Holding History

Boston Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$24.6M	Buy	649,335 +141,846	+28%	+$6.54M	0.02%	360
2026 Q2	$24.3M	Buy	507,489 +362,469	+250%	+$15.6M	0.02%	369
2026 Q1	$5.33M	Sell	145,020 -5,231,804	-97%	-$248M	0.01%	480
2025 Q4	$276M	Sell	5,376,824 -194,193	-3%	-$9.9M	0.29%	122
2025 Q3	$310M	Buy	+5,571,017	New	+$326M	0.32%	108
2020 Q2	–	Sell	-2,499,362	Closed	-$75.2M	–	686
2020 Q1	$75.2M	Sell	2,499,362 -1,674,248	-40%	-$49.9M	0.15%	171
2019 Q4	$121M	Sell	4,173,610 -176,992	-4%	-$4.9M	0.16%	172
2019 Q3	$113M	Sell	4,350,602 -117,540	-3%	-$2.97M	0.15%	173
2019 Q2	$114M	Sell	4,468,142 -47,278	-1%	-$1.17M	0.15%	175
2019 Q1	$118M	Buy	4,515,420 +175,756	+4%	+$4.32M	0.16%	166
2018 Q4	$100M	Buy	+4,339,664	New	+$96.4M	0.14%	176

Other funds holding NVO

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Everett Harris & Co Los Angeles, California $8.46B AUM 13.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Saratoga Research & Investment Management Saratoga, California $1.82B AUM 11.8% 1-Year Est. Return

Markel Group Glen Allen, Virginia $12.8B AUM 8.77% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return

Boston Partners's NVO Position: Q3 2026 in Review

Boston Partners increased its Novo Nordisk (NVO) stake by 28% in Q3 2026, buying an estimated $6.54M and bringing the position to 649,335 shares worth $24.6M. The position accounts for 0.02% of the portfolio, ranked #360.

Boston Partners first reported a position in NVO in Q4 2018 and has held it in 11 quarters since. The position peaked at $310M in Q3 2025. 816 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

Boston Partners held 649,335 shares of Novo Nordisk worth $24.6M as of Q3 2026.
Boston Partners bought 141,846 Novo Nordisk shares in Q3 2026, an estimated $6.54M.
Novo Nordisk made up 0.02% of Boston Partners's portfolio in Q3 2026, its #360 holding.
Boston Partners first reported a position in Novo Nordisk in Q4 2018 and has held it in 11 quarters since.
Boston Partners's Novo Nordisk position peaked at $310M in Q3 2025.
816 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Boston Partners's 13F filing for Q3 2026, filed 10 Nov 2026.